IRB #

STUDY00016379

Title

C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy

Principal Investigator

Kathleen Kemmer

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of the study drug, MLN0128 in combination with fulvestrant, in patients with advanced or metastatic Breast Cancer that has progressed during or after aromatase inhibitor therapy.

Medical Condition(s)

Advanced/Metastatic Breast Cancer
ER-positive/HER-2-negative

Eligibility Criteria

Female, postmenopausal
≥ 18 years of age
ER-positive/HER-2-negative Advanced or Metastatic Breast Cancer
Previously treated with aromatase inhibitor therapy and progressed

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.

Minors Included

No

Contact

OHSU Knight Cancer Institute Information line 503-494-1080
trials@ohsu.edu

Sponsor

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited

Recruitment End

12/31/2030

Compensation Provided

No


Go Back